Cargando…

Myocarditis Following COVID-19 Vaccination

Myocarditis is an established but rare adverse event following administration of messenger RNA–based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild a...

Descripción completa

Detalles Bibliográficos
Autores principales: Marschner, Constantin A., Shaw, Kirsten E., Tijmes, Felipe Sanchez, Fronza, Matteo, Khullar, Sharmila, Seidman, Michael A., Thavendiranathan, Paaladinesh, Udell, Jacob A., Wald, Rachel M., Hanneman, Kate
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072816/
https://www.ncbi.nlm.nih.gov/pubmed/35851461
http://dx.doi.org/10.1016/j.ccl.2022.05.002
_version_ 1784701144554012672
author Marschner, Constantin A.
Shaw, Kirsten E.
Tijmes, Felipe Sanchez
Fronza, Matteo
Khullar, Sharmila
Seidman, Michael A.
Thavendiranathan, Paaladinesh
Udell, Jacob A.
Wald, Rachel M.
Hanneman, Kate
author_facet Marschner, Constantin A.
Shaw, Kirsten E.
Tijmes, Felipe Sanchez
Fronza, Matteo
Khullar, Sharmila
Seidman, Michael A.
Thavendiranathan, Paaladinesh
Udell, Jacob A.
Wald, Rachel M.
Hanneman, Kate
author_sort Marschner, Constantin A.
collection PubMed
description Myocarditis is an established but rare adverse event following administration of messenger RNA–based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings, and proposed pathophysiologic mechanisms.
format Online
Article
Text
id pubmed-9072816
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-90728162022-05-06 Myocarditis Following COVID-19 Vaccination Marschner, Constantin A. Shaw, Kirsten E. Tijmes, Felipe Sanchez Fronza, Matteo Khullar, Sharmila Seidman, Michael A. Thavendiranathan, Paaladinesh Udell, Jacob A. Wald, Rachel M. Hanneman, Kate Cardiol Clin Article Myocarditis is an established but rare adverse event following administration of messenger RNA–based coronavirus disease 2019 (COVID-19) vaccines and is most common in male adolescents and young adults. Symptoms typically develop within a few days of vaccine administration. Most patients have mild abnormalities on cardiac imaging with rapid clinical improvement with standard treatment. However, longer term follow-up is needed to determine whether imaging abnormalities persist, to evaluate for adverse outcomes, and to understand the risk associated with subsequent vaccination. The purpose of the review is to evaluate the current literature related to myocarditis following COVID-19 vaccination, including the incidence, risk factors, clinical course, imaging findings, and proposed pathophysiologic mechanisms. Elsevier Inc. 2022-08 2022-05-06 /pmc/articles/PMC9072816/ /pubmed/35851461 http://dx.doi.org/10.1016/j.ccl.2022.05.002 Text en © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Marschner, Constantin A.
Shaw, Kirsten E.
Tijmes, Felipe Sanchez
Fronza, Matteo
Khullar, Sharmila
Seidman, Michael A.
Thavendiranathan, Paaladinesh
Udell, Jacob A.
Wald, Rachel M.
Hanneman, Kate
Myocarditis Following COVID-19 Vaccination
title Myocarditis Following COVID-19 Vaccination
title_full Myocarditis Following COVID-19 Vaccination
title_fullStr Myocarditis Following COVID-19 Vaccination
title_full_unstemmed Myocarditis Following COVID-19 Vaccination
title_short Myocarditis Following COVID-19 Vaccination
title_sort myocarditis following covid-19 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072816/
https://www.ncbi.nlm.nih.gov/pubmed/35851461
http://dx.doi.org/10.1016/j.ccl.2022.05.002
work_keys_str_mv AT marschnerconstantina myocarditisfollowingcovid19vaccination
AT shawkirstene myocarditisfollowingcovid19vaccination
AT tijmesfelipesanchez myocarditisfollowingcovid19vaccination
AT fronzamatteo myocarditisfollowingcovid19vaccination
AT khullarsharmila myocarditisfollowingcovid19vaccination
AT seidmanmichaela myocarditisfollowingcovid19vaccination
AT thavendiranathanpaaladinesh myocarditisfollowingcovid19vaccination
AT udelljacoba myocarditisfollowingcovid19vaccination
AT waldrachelm myocarditisfollowingcovid19vaccination
AT hannemankate myocarditisfollowingcovid19vaccination